Imigran Sprint

Sumatriptan succinate, the active ingredient in Imigran Sprint, is a Triptan (selective 5-HT1B/1D receptor agonist) presented as an oral tablet for oral use. It treats acute migraine attacks in adults and adolescents. GNH USA supplies Imigran Sprint as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imigran Sprint belongs to the triptan class and is used for acute migraine and related headache disorders.

Migraine (with or without aura): provides rapid relief of headache pain, nausea, photophobia and phonophobia. Adolescent migraine (12‑17 years): offers similar relief as in adults for qualified patients. Episodic cluster headache: may abort an individual headache attack during a cluster period.

Common Side Effects: - Chest pressure or tightness - Tingling or numbness in the face or extremities - Warmth or flushing sensation - Nausea or mild gastrointestinal upset

Serious or Rare Side Effects: - Coronary artery spasm or myocardial infarction - Severe hypertension or hypertensive crisis - Serotonin syndrome, especially when combined with other serotonergic agents

Before prescribing Imigran Sprint, consider the following precautions: - Cardiovascular disease: avoid in patients with coronary artery disease, uncontrolled hypertension or history of myocardial infarction. - Hemiplegic or basilar migraine: contraindicated due to increased risk of cerebrovascular events. - Concomitant serotonergic drugs: monitor for signs of serotonin syndrome. - Pregnancy and lactation: safety not established; use only if potential benefit justifies risk. - Storage: Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imigran Sprint may interact with several drug classes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension. - Other triptans or ergot alkaloids: additive vasoconstriction. - Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs): increased serotonin syndrome risk. - Certain antihypertensives (e.g., propranolol) when combined may raise sumatriptan levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase plasma concentrations. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Beta‑blockers: monitor blood pressure and heart rate.